Caribou's Vispa-cel Shows 82% ORR, Advances to Phase 3; CB-011 Hits 92% ORR in Follow-up
CRBU sits 74% above its 52-week low of $1.04.
Summary
Caribou Biosciences reported strong Phase 1 follow-up data for two key allogeneic CAR-T cell therapies, with manageable safety profiles. Vispa-cel achieved an 82% Overall Response Rate (ORR) and 67% Complete Response (CR) in 2L LBCL, with a 17.1-month median PFS. Separately, CB-011 showed a 92% ORR and 83% complete response or better in BCMA-naïve patients. This positive clinical data significantly de-risks the company's pipeline, especially with vispa-cel's Phase 3 trial design now aligned with the FDA. This builds on the FDA RMAT designation CB-011 received in March. The company is scheduled to present vispa-cel data at EHA on June 12 and CB-011 data on June 14.
At the time of this announcement, CRBU was trading at $1.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $177.5M. The 52-week trading range was $1.04 to $3.54. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.